Cross-protection against acute Staphylococcus aureus lung infection in mice by a D-Glutamate Auxotrophic vaccine candidate

UDC.coleccionInvestigaciónes_ES
UDC.departamentoFisioterapia, Medicina e Ciencias Biomédicases_ES
UDC.grupoInvInvestigación en Microbiología (INIBIC)es_ES
UDC.institutoCentroINIBIC - Instituto de Investigacións Biomédicas de A Coruñaes_ES
UDC.issue2es_ES
UDC.journalTitleVaccineses_ES
UDC.startPage210es_ES
UDC.volume11es_ES
dc.contributor.authorGarcía, Patricia
dc.contributor.authorCabral, M. P.
dc.contributor.authorBeceiro Casas, Alejandro
dc.contributor.authorMosocos, Miriam
dc.contributor.authorBou, Germán
dc.date.accessioned2025-02-06T10:32:16Z
dc.date.available2025-02-06T10:32:16Z
dc.date.issued2023-01-17
dc.description.abstract[Abstract] Staphylococcus aureus is regarded as a threatening bacterial pathogen causing invasive pneumonia in healthcare settings and in the community. The continuous emergence of multidrug resistant strains is narrowing the treatment options for these infections. The development of an effective S. aureus vaccine is, therefore, a global priority. We have previously developed a vaccine candidate, 132 ΔmurI Δdat, which is auxotrophic for D-glutamate, and protects against sepsis caused by S. aureus. In the present study, we explored the potential of this vaccine candidate to prevent staphylococcal pneumonia, by using an acute lung infection model in BALB/c mice. Intranasal inoculation of the vaccine strain yielded transitory colonization of the lung tissue, stimulated production of relevant serum IgG and secretory IgA antibodies in the lung and distal vaginal mucosa and conferred cross-protection to acute pneumonia caused by clinically important S. aureus strains. Although these findings are promising, additional research is needed to minimize dose-dependent toxicity for safer intranasal immunization with this vaccine candidate.es_ES
dc.description.sponsorshipThis work was supported by a grant from the Servicio Galego de Saúde (SERGAS)-Galician Healthcare Service (Programs “Innova Saúde”), the Spanish Network for Research in Infectious Diseases (RD12/0015/0014 and RD16/0016/0006) and Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC). The work was funded by Instituto Carlos III (ISCIII) through projects PI15/00860, PI18/00501 and PI21/00704 to GB; and PI20/01212 to AB, co-funded by European Regional Development Fund “A way to make Europe”; and by GAIN–Agencia Gallega de Innovación–Consellería de Economía, Emprego e Industria through the project IN607D 2021/12 to AB. PG was supported by the Spanish Network for Research in Infectious Diseases (RD12/0015/0014 and RD16/0016/0006). MPC was supported by a PhD scholarship (SFRH/BD/64740/2009) from Portugal and POPH/FSE.es_ES
dc.description.sponsorshipXunta de Galicia; RD12/0015/0014es_ES
dc.description.sponsorshipXunta de Galicia; RD16/0016/0006es_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/MINECO/Programa Estatal de I+D+I Orientada a los Retos de la Sociedad/PI15%2F00860/ES/Desarrollo de una plataforma universal de vacunas bacterianas vivas atenuadas auxótrofas para D-glutamato: prevención y erradicación de infecciones por bacterias multirresistenteses_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/ISCIII/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/PI18%2F00501/ES/DISEÑO Y DESARROLLO DE UNA VACUNA PARA LA PREVENCION Y ERRADICACION DE LAS INFECCIONES RESPIRATORIAS AGUDAS Y CRONICAS (FIBROSIS QUISTICA) CAUSADAS POR PSEUDOMONAS AERUGINOSAes_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/ISCIII/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/PI21%2F00704/ES/VACUNAS AUXOTROFAS ORALES PARA LA ERRADICACION DE BACTERIAS INTESTINALES: COLONIZACIÓN INTESTINAL POR KLEBSIELLA PNEUMONIAE MULTIRRESISTENTE COMO MODELOes_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/ISCIII/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/PI20%2F01212/ES/DESARROLLO Y EVALUACION DE NUEVAS MOLECULAS ANTIMICROBIANAS DIRIGIDAS A PATOGENOS MULTIRRESISTENTES (INHIBIDORES DE ß-LACTAMASAS Y CONJUGADOS TETRACICLINAS-SIDEROFOROS). ESTUDIO NACIONAL ACINETOBACTER SPP.es_ES
dc.description.sponsorshipXunta de Galicia; IN607D 2021/12es_ES
dc.identifier.citationGarcía P, Cabral MP, Beceiro A, Moscoso M, Bou G. Cross-Protection against Acute Staphylococcus aureus Lung Infection in Mice by a D-Glutamate Auxotrophic Vaccine Candidate. Vaccines (Basel). 2023 Jan 17;11(2):210.es_ES
dc.identifier.doi10.3390/vaccines11020210
dc.identifier.issn2076-393X
dc.identifier.urihttp://hdl.handle.net/2183/41083
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relation.urihttps://doi.org/10.3390/vaccines11020210es_ES
dc.rightsCreative Commons Attribution 4.0 International License (CC-BY 4.0)es_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectD-amino acid transaminase genees_ES
dc.subjectStaphylococcus aureuses_ES
dc.subjectAcute lung infection modeles_ES
dc.subjectAuxotrophices_ES
dc.subjectGlutamate racemase genees_ES
dc.subjectIntranasal immunizationes_ES
dc.subjectLive-attenuated vaccinees_ES
dc.titleCross-protection against acute Staphylococcus aureus lung infection in mice by a D-Glutamate Auxotrophic vaccine candidatees_ES
dc.typejournal articlees_ES
dspace.entity.typePublication
relation.isAuthorOfPublication909e08d1-6ed1-4b99-9e9e-c64eb72e7dea
relation.isAuthorOfPublication.latestForDiscovery909e08d1-6ed1-4b99-9e9e-c64eb72e7dea

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Garcia_CrossProtection_2023.pdf
Size:
1.82 MB
Format:
Adobe Portable Document Format
Description: